These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7940928)

  • 1. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
    Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
    Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.
    Sketris IS; Lawen JG; Beauregard-Zollinger L; Belitsky P; Landsberg D; Givner ML; Keown P
    Transplant Proc; 1994 Oct; 26(5):2961-3. PubMed ID: 7940935
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical experience in transferring kidney transplant patients from sandimmun to sandimmun neoral--results after 6 months.
    Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J
    Transplant Proc; 1995 Oct; 27(5):2679-82. PubMed ID: 7482873
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
    White M; Pelletier GB; Tan A; Jesina C; Carrier M
    J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
    Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
    Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month.
    Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J
    Transplant Proc; 1994 Oct; 26(5):2944-8. PubMed ID: 7940929
    [No Abstract]   [Full Text] [Related]  

  • 8. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of Neoral in heart transplant recipients.
    Mikhail G; Eadon H; Leaver N; Yacoub M
    Transplant Proc; 1994 Oct; 26(5):2985-7. PubMed ID: 7940943
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 11. Sandimmun neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients.
    Taesch S; Niese D; Mueller EA
    Transplant Proc; 1994 Dec; 26(6):3147-9. PubMed ID: 7998097
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients.
    Cooney GF; Dunn SP; Kaiser B; Kulinsky AV; Mochon M; Heifets M
    Transplant Proc; 1994 Oct; 26(5):2779-80. PubMed ID: 7940876
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from Sandimmune to Neoral in stable renal transplant recipients. Sandoz Study Group OLN-353.
    Pescovitz MD
    Transplant Proc; 1996 Aug; 28(4):2196-8. PubMed ID: 8769198
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood cyclosporin A and metabolite kinetic profiles after administration of Sandimmune soft gelatine capsules and Neoral in transplant recipients.
    Vernillet L; Kovarik JM; Freiburghaus R; Schaub P; Mueller EA; Niederberger W; Zehender H
    Transplant Proc; 1994 Oct; 26(5):2964-8. PubMed ID: 7940936
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients.
    Cole E; Maham N; Cardella C; Cattran D; Fenton S; Hamel J; O'Grady C; Smith R
    Transplantation; 2003 Jun; 75(12):2086-90. PubMed ID: 12829917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
    Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
    Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.